Page 5 - Diffuse Largeb Cell News Today

Press release content from Business Wire. The AP news staff was not involved in its creation.

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...

22.03.2022 - DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL 22.03.2022 / 21:01 The issuer ... Seite 1

BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous15.03.2022 / 21:01 The issuer is solely responsible for the content of this announcement.Media ReleaseNational Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology...

National Comprehensive Cancer Network® Updates Designation of Monjuvi® to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas BOSTON,... | March 15, 2022

AstraZeneca will present new data underscoring its commitment to transforming haematologic cancer care at the 63rd American Society of Hematology

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring According to researchers at Marshall University, a maternal diet rich in Omega-3 fatty acids protects from breast cancer development in offspring. In a new study recently published by Frontiers in Cell and Developmental Biology, researchers noted a significant difference in mice from mothers that were fed a diet rich in canola oil, compared with mothers fed a diet rich in corn oil. A maternal Omega 3-rich diet affected g...

frontMIND Study Evaluating Tafasitamab Combination as a  First-line Treatment for Diffuse Large B-Cell Lymphoma PLANEGG/MUNICH, Germany and WILMINGTON, Del., USA - May 11, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as firs...

University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy University Hospitals offering new cancer treatment for patients and last updated 2021-05-08 10:11:56-04 CLEVELAND — When 61-year-old Ken Anderson was diagnosed with Multiple Myeloma 3 years ago, he didn’t know what to expect. “It kind of hits you. It hits you hard,” he said. “It’s a blood cancer, and it’s in your bone marrow, and it degenerates your bones is what it doe...